ArticleCureus2026
An Evaluation of Endobronchial Ultrasound-Transbronchial Needle Aspiration (EBUS-TBNA): Molecular Diagnoses and Patient Satisfaction.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimEndobronchial ultrasound-transbronchial needle aspiration (EBUS-TBNA) is a minimally invasive procedure that collects biopsies in patients with mediastinal and/or hilar lymphadenopathy, often in lung cancer or sarcoidosis. Cancerous biopsies can undergo molecular testing to identify mutations, which may be targeted by immunotherapy. The role of EBUS-TBNA in molecular outcomes has not been studied previously in the United Kingdom. This study also examines patient demographics and satisfaction to comprehensively evaluate EBUS-TBNA. This study aimed to evaluate the EBUS-TBNA service at University Hospital Southampton (UHS), focusing on patient demographics, satisfaction, diagnostic outcomes, procedural statistics, and identifying targetable mutations for immunotherapy.
methodA total of 306 patients were studied retrospectively, and 39 were studied prospectively, using a questionnaire. Data on their characteristics, reports, diagnoses, and molecular tests were recorded and analyzed using SPSS version 29.
resultsA total of 47.12% (n = 131) patients were diagnosed with primary lung cancer, 23.38% (n = 65) with sarcoidosis, 9.71% (n = 27) with metastatic cancer, and 1.95% (n = 7) with other diagnoses, such as tuberculosis. Primary lung cancer was categorized as adenocarcinoma (52.31%, n = 68), squamous cell carcinoma (SCC) (25.38%, n = 33), and small cell carcinoma (SCLC) (16.92%, n = 23). Of the primary cancer cases, 60.31% (n = 79) underwent molecular testing. In this cohort, 29.41% (n = 20) of adenocarcinoma cases tested positive for a targetable mutation as follows: 85% (n = 17) were KRAS G12C, and 15% (n = 3) were the EGFR E19del. Overall, 15.27% (n = 20) of EBUS-TBNA procedures for primary lung cancer revealed a clinically actionable variant. Of the 39 patients surveyed, there was a significant difference between the pain experienced (median = 2/10, IQR = 4) and the expected pain (median = 5/10, IQR = 6), as assessed by a Wilcoxon signed-rank test (z = -2.91, p = 0.004). The average staff experience during the EBUS was 9.87/10 (SD = 0.47), and 55.85% (n = 21) waited <1 week for the procedure.
conclusionsEBUS-TBNA's role in diagnosing various conditions, especially primary lung cancer, is clear. Clinically, EBUS-TBNA provides genetic diagnoses, which can enable immunotherapy. Patient satisfaction is high, with patients expressing relief after the procedure and finding the staff exceptional.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.